The 3-hydroxypyridin-4-ones more effectively chelate aluminum in a rabbit model of aluminum intoxication than does desferrioxamine

Drug Metabolism and Disposition

Volumn 24, Issue 1, 1996, Pages 105-111

  Yokel, Roberta ^a,b,c   Meurer, Kathryn A ^a   Skinner, Thomas L ^a   Fredenburg, Andrea M ^b  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; 3 HYDROXY 4 PYRIDONE DERIVATIVE; ALUMINUM; ALUMINUM LACTATE; DEFERIPRONE; DEFEROXAMINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHELATION; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG EFFICACY; DRUG URINE LEVEL; HEAVY METAL POISONING; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; LIPOPHILICITY; LIVER TOXICITY; MALE; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; TOXICOKINETICS;

ALUMINUM; ANIMALS; BILE; CHELATING AGENTS; DEFEROXAMINE; DISEASE MODELS, ANIMAL; MALE; PYRIDONES; RABBITS;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0030071067     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. T. P. Flaten, A. C. Alfrey, J. D. Birchall, and R. A. Yokel: The status and future concerns of clinical and environmental aluminum toxicology. J. Toxicol. Environ. Health (1996).
2. M. Perazella and E. Brown: Acute aluminum toxicity and alum bladder irrigation in patients with renal failure. Am. J. Kidney Dis. 21, 44-46 (1993).
3. P. Ackrill, A. J. Ralston, and J. P. Day: Role of desferrioxamine in the treatment of dialysis encephalopathy. Kidney Int. 18 (Suppl.), S-104-S-107 (1986).
4. D. R. Blake, P. Winyard, J. Lunec, A. Williams, P. A. Good, S. J. Crewes, J. M. C. Gurteridge, D. Rowley, B. Halliwell, A. Cornish, and R. C. Hider: Cerebral and ocular toxicity induced by desferrioxamine. Q. J. Med. 56, 345-355 (1985).
5. J. R. Boelaert, A. Z. Fenves, and J. W. Coburn: Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am. J. Kidney Dis. 18, 660-667 (1991).
6. R. A. Yokel and P. J. McNamara: Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. Toxicol. Appl. Pharmacol. 95, 32-43 (1988).
7. D. D. Allen, C. Orvig, and R. A. Yokel: Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: Implications for aluminum redistribution subsequent to chelation therapy. Toxicology 92, 193-202 (1994).
8. R. J. Motekaitis and A. E. Martell: Stabilities of the iron(III) chelates of 1,2-dimethyl-3-hydroxy-4-pyridinone and related ligands. Inorg. Chim. Acta 183, 71-80 (1991).
9. A. C. Alfrey, A. Hegg, and P. Craswell: Metabolism and toxicity of aluminum in renal failure. Am. J. Clin. Nutr. 33, 1509-1516 (1980).
10. R. A. Yokel: Persistent aluminum accumulation after prolonged systemic aluminum exposure. Biol. Trace Elem. Res. 5, 467-474 (1983).